| Product Code: ETC8891136 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Portugal`s import shipments of PD-1 and PD-L1 inhibitors in 2024 continued to be dominated by key European countries such as Germany, Spain, Belgium, Metropolitan France, and the Netherlands. The market showed a stable level of competition with a low Herfindahl-Hirschman Index (HHI) indicating a diversified import market. The compound annual growth rate (CAGR) from 2020 to 2024 was moderate at 2.5%, while the growth rate for the previous year (2023-24) stood at 2.21%. These numbers suggest a steady growth trajectory for the importation of PD-1 and PD-L1 inhibitors into Portugal.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Portugal PD-1 and PD-L1 Inhibitors Market Overview |
3.1 Portugal Country Macro Economic Indicators |
3.2 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 Portugal PD-1 and PD-L1 Inhibitors Market - Industry Life Cycle |
3.4 Portugal PD-1 and PD-L1 Inhibitors Market - Porter's Five Forces |
3.5 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume Share, By Inhibitors, 2021 & 2031F |
3.6 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Portugal PD-1 and PD-L1 Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of cancer and the growing need for effective treatment options. |
4.2.2 Technological advancements in the development of PD-1 and PD-L1 inhibitors. |
4.2.3 Rising investments in healthcare infrastructure and research development. |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approvals. |
4.3.2 High cost associated with PD-1 and PD-L1 inhibitors. |
4.3.3 Potential side effects and limited efficacy of these inhibitors in certain patient populations. |
5 Portugal PD-1 and PD-L1 Inhibitors Market Trends |
6 Portugal PD-1 and PD-L1 Inhibitors Market, By Types |
6.1 Portugal PD-1 and PD-L1 Inhibitors Market, By Inhibitors |
6.1.1 Overview and Analysis |
6.1.2 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Inhibitors, 2021- 2031F |
6.1.3 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By PD-1 Inhibitors, 2021- 2031F |
6.1.4 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By PD-L1 Inhibitors, 2021- 2031F |
6.2 Portugal PD-1 and PD-L1 Inhibitors Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Hodgkin Lymphoma, 2021- 2031F |
6.2.3 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Kidney Cancer, 2021- 2031F |
6.2.4 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Melanoma, 2021- 2031F |
6.2.5 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Non-small Cell Lung Cancer, 2021- 2031F |
6.2.6 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Other Applications, 2021- 2031F |
6.3 Portugal PD-1 and PD-L1 Inhibitors Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.3.4 Portugal PD-1 and PD-L1 Inhibitors Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Portugal PD-1 and PD-L1 Inhibitors Market Import-Export Trade Statistics |
7.1 Portugal PD-1 and PD-L1 Inhibitors Market Export to Major Countries |
7.2 Portugal PD-1 and PD-L1 Inhibitors Market Imports from Major Countries |
8 Portugal PD-1 and PD-L1 Inhibitors Market Key Performance Indicators |
8.1 Clinical trial success rates for new PD-1 and PD-L1 inhibitors. |
8.2 Adoption rates of immunotherapy treatments in cancer care. |
8.3 Patient response rates and survival outcomes with PD-1 and PD-L1 inhibitors. |
9 Portugal PD-1 and PD-L1 Inhibitors Market - Opportunity Assessment |
9.1 Portugal PD-1 and PD-L1 Inhibitors Market Opportunity Assessment, By Inhibitors, 2021 & 2031F |
9.2 Portugal PD-1 and PD-L1 Inhibitors Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Portugal PD-1 and PD-L1 Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Portugal PD-1 and PD-L1 Inhibitors Market - Competitive Landscape |
10.1 Portugal PD-1 and PD-L1 Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 Portugal PD-1 and PD-L1 Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |